Company Filing History:
Years Active: 1985-1989
Title: Paul H. Ehrlich: Innovator in Immunoassay Technology
Introduction
Paul H. Ehrlich is a distinguished inventor based in New York, NY (US), known for his significant contributions to the field of immunoassay technology. With a total of three patents to his name, Ehrlich has made notable advancements in the detection and measurement of human chorionic gonadotropin (hCG), a hormone critical in various medical diagnostics.
Latest Patents
Ehrlich's latest patent focuses on an immunoassay for detecting and measuring hCG in a sample. This innovative method includes an antibody directed to the carboxy terminal portion of the beta subunit of hCG, along with a monoclonal antibody that binds to a different determinant on hCG. This design allows both antibodies to simultaneously bind to hCG, enhancing the assay's effectiveness. In a preferred embodiment, the immunoassay for hCG or hCG beta in urine utilizes a purified, labeled serum-derived antibody and a matrix-bound monoclonal antibody, ensuring that both can bind to hCG or hCG beta effectively.
Career Highlights
Ehrlich's career is marked by his role at Columbia University, where he has contributed to groundbreaking research in immunology and diagnostics. His work has paved the way for improved sensitivity in diagnostic assays, particularly for important antigens like hCG.
Collaborations
Throughout his career, Ehrlich has collaborated with notable colleagues, including Robert E. Canfield and William R. Moyle. These partnerships have further enriched his research and innovations in the field.
Conclusion
Paul H. Ehrlich's contributions to immunoassay technology have significantly impacted medical diagnostics. His innovative patents and collaborations reflect his dedication to advancing the field and improving healthcare outcomes.